

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 5/06, 5/08, 5/20, C12P 21/08, C07K 16/28, 7/08	A1	(11) International Publication Number: WO 00/55305 (43) International Publication Date: 21 September 2000 (21.09.00)
(21) International Application Number: PCT/US00/05898 (22) International Filing Date: 8 March 2000 (08.03.00) (30) Priority Data: 60/124,253 12 March 1999 (12.03.99) US (71) Applicant: ORTHO-MCNEIL PHARMACEUTICAL, INC. [US/US]; U.S. Route 202, Raritan, NJ 08873-1102 (US). (72) Inventor: LETURCQ, Didier; 3991 Crown Point Drive, San Diego, CA 92109 (US). (74) Agents: CIAMPORCERO, Audley et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933-7003 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: METHOD OF ISOLATING CD8 ⁺ CELLS, AND RELATED HYBRIDOMA CELLS, ANTIBODIES AND POLYPEPTIDES		
(57) Abstract This invention provides a method of isolating CD8 ⁺ cells which employs an antibody which specifically binds to CD8 molecules present on the surface of CD8 ⁺ cells but does not activate the CD8 ⁺ cells once bound. This invention also provides related hybridoma cell lines, monoclonal antibodies, antigenic polypeptides, isolated CD8 ⁺ cells, and kits.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD OF ISOLATING CD8⁺ CELLS, AND RELATED HYBRIDOMA CELLS,
ANTIBODIES AND POLYPEPTIDES

5

Throughout this application, various publications are cited. The disclosure of these publications is hereby incorporated by reference into this application to describe more fully the state of the art to which this invention
10 pertains.

Field of the Invention

This invention relates to a positive selection method
15 for isolating CD8⁺ cells using certain CD8-specific antibodies. The isolated CD8⁺ cells have importance as vehicles for combating viral infections and tumors.

Background of the Invention

20

In humans, CD8⁺ cells play a vital role in the immune system's ability to defend against potentially harmful foreign entities, such as bacteria and viruses [1]. CD8⁺ cells circulate in the blood and possess on their surface
25 the CD8 protein. When necessary, these cells are converted into cytotoxic cells (i.e. cell-killing cells) which proceed to destroy foreign cells, viruses, and other harmful pathogens present in the subject [2]. Because of CD8⁺ cells' effective role in host defense, they hold
30 great potential in isolated form as therapeutics for treating disorders such as viral infections and malignancies [3].

In the past, purification of human CD8⁺ cells has
35 been achieved by negative selection. Specifically,

peripheral blood mononuclear cells ("PBMC's") are incubated with a cocktail of monoclonal antibodies specific for non-CD8 sub-populations. These sub-populations include, for example, B-cells, CD4⁺ cells, NK
5 cells, macrophages and neutrophils, and each contains specific, non-CD8 "markers". The sub-populations are then removed from the resulting antibody cocktail using magnetic beads [4]. This technique has certain major disadvantages. The first is that several monoclonal
10 antibodies are required for removing non-CD8⁺ cells. The second is that the resulting CD8⁺ population suffers from contamination from non-CD8⁺ cells that possess relatively low levels of non-CD8 markers. Finally, when a magnetic separation procedure is used to remove all non-CD8⁺ cells,
15 a large number of magnetic beads are needed.

Summary of the Invention

This invention provides a method of isolating CD8⁺ cells which comprises the steps of

- 5 (a) contacting a sample of isolated peripheral mononuclear blood cells with a first antibody which specifically binds to the sequence AAEGLDTQRFSG, or portion thereof, on CD8 molecules present on the surface of CD8⁺ cells
10 but does not activate the CD8⁺ cells once bound thereto, under conditions permitting the formation of a first complex between the CD8⁺ cell and first antibody;
- 15 (b) separating from the sample any first antibody not present in the resulting first complex;
- 20 (c) contacting the sample with a second, immobilized antibody which specifically binds to the first antibody in the first complex, under conditions permitting the formation of an immobilized, second complex between the first complex and the second antibody, thereby immobilizing the CD8⁺ cells present in the sample;
- 25 (d) separating from the resulting immobilized second complex the cells present in the sample which were not immobilized in step (c);
- 30 (e) contacting the immobilized second complex under suitable conditions with an agent which causes the dissociation of the second complex into CD8⁺ cells and an immobilized third complex between the first antibody and second antibody; and
- (f) separating the immobilized third complex from the CD8⁺ cells, thereby isolating the CD8⁺ cells.

This invention also provides a hybridoma cell line which produces a monoclonal antibody which specifically binds to CD8 molecules present on the surface of CD8⁺ cells but does not activate the CD8⁺ cells. This
5 invention further provides monoclonal antibodies produced by each of the instant hybridoma cell lines. Finally, this invention provides related polypeptides, isolated CD8⁺ cells and kits.

Detailed Description of the Invention

The hybridoma cell lines designated 37B1 and 8G6 were deposited pursuant to, and in satisfaction of, the requirements of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Virginia 2010-2209 under ATCC Accession Nos. HB-12441 and HB-12657, respectively.

This invention provides a method of isolating CD8⁺ cells by employing an anti-CD8 antibody, along with certain other reagents. Specifically, this invention provides a method of isolating CD8⁺ cells which comprises the steps of

- (a) contacting a sample of isolated peripheral mononuclear blood cells with a first antibody which specifically binds to the sequence AAEGLDTQRFSG, or portion thereof, on CD8 molecules present on the surface of CD8⁺ cells but does not activate the CD8⁺ cells once bound thereto, under conditions permitting the formation of a first complex between the CD8⁺ cell and first antibody;
- (b) separating from the sample any first antibody not present in the resulting first complex;
- (c) contacting the sample with a second, immobilized antibody which specifically binds to the first antibody in the first complex, under conditions permitting the formation of an immobilized, second complex between the first complex and the second antibody, thereby immobilizing the CD8⁺ cells present in the sample;

- (d) separating from the resulting immobilized second complex the cells present in the sample which were not immobilized in step (c);
- 5 (e) contacting the immobilized second complex under suitable conditions with an agent which causes the dissociation of the second complex into CD8⁺ cells and an immobilized third complex between the first antibody and second antibody; and
- 10 (f) separating the immobilized third complex from the CD8⁺ cells, thereby isolating the CD8⁺ cells.

As used herein, a "CD8⁺ cell" means a T-cell having on its surface the CD8 protein. In the preferred
15 embodiment, the CD8⁺ cells are human CD8⁺ cells. The CD8⁺ cells can be from any CD8⁺ cell-possessing species. "Isolating" CD8⁺ cells means obtaining a population of peripheral mononuclear blood cells wherein the ratio of CD8⁺ cells to non-CD8⁺ cells is at least about 7:1. In
20 the preferred embodiment of this invention, this ratio is at least about 9:1.

This invention employs several types of antibodies which specifically bind to given epitopes. More
25 particularly, this invention uses a "first antibody" which specifically binds to the sequence AAEGLDLTQRFSG, or portion thereof, on CD8 molecules present on the surface of CD8⁺ cells but does not activate the CD8⁺ cells once bound thereto. Here, CD8⁺ cell "activation" means causing
30 CD8⁺ cells to express γ -interferon (" γ -IFN"). This activation can be measured using routine methods such as sandwich ELISA assays, which can be performed using commercially available kits.

Such first antibodies include, but are not limited to, the monoclonal antibodies produced by the hybridoma cell lines 37B1 (ATCC Accession No. HB-12441) and 8G6 (ATCC Accession No. HB-12657). Conditions which permit these antibodies to bind to but not activate CD8⁺ cells are well known in the art. These conditions are described, for example, in a suitable buffer such as Ca²⁺ and Mg²⁺-free Dulbecco's Phosphate Buffer Saline (DPBS) containing 1% Human Serum Albumin (HSA) and 0.2% sodium citrate and gentle mixing by "end over end" rotation on a rotator set at 4 rpm.

As used herein, the term "antibody" includes, but is not limited to, both naturally occurring and non-naturally occurring antibodies. Specifically, the term "antibody" includes polyclonal and monoclonal antibodies, and binding fragments thereof. Furthermore, the term "antibody" includes chimeric antibodies and wholly synthetic antibodies, and fragments thereof. In one embodiment, the antibody is a monoclonal antibody. The monoclonal antibody can be human, or that of another species including, for example, mouse and rabbit. In this invention, an antibody which "specifically" binds to a stated epitope binds to that epitope with a dissociation constant of at least about 10-fold less than the dissociation constant with which it binds to any other epitope. In one embodiment, this dissociation constant ratio is at least about 100. In the preferred embodiment, this dissociation constant ratio is at least about 10³.

The "second antibody" used in the instant method can be any antibody which specifically recognizes an epitope on any portion of the first antibody. In the preferred embodiment, the second antibody specifically recognizes a

portion of the constant (Fc) region of the first antibody. Such anti-Fc antibodies are commercially available and include, for example, sheep anti-mouse antibody immobilized on magnetic beads [5].

5

The agent that causes dissociation of the immobilized second complex into CD8⁺ cells and immobilized antibodies can be any agent which successfully competes with the CD8 molecule for specific binding to the first antibody. In the preferred embodiment, this agent is the polypeptide designated CD8-3 having the sequence AAEGLDTQRFSG. In one embodiment, the immobilized second antibody comprises an antibody operably affixed to a magnetic bead.

15 This invention also provides a hybridoma cell line which produces a monoclonal antibody which specifically binds to CD8 molecules present on the surface of CD8⁺ cells but does not activate the CD8⁺ cells. In one embodiment, the hybridoma cell line is selected from the cell lines designated 37B1 (ATCC Accession No. HB-12441) and 8G6 (ATCC Accession No. HB-12657). This invention further provides the monoclonal antibodies produced by each of the instant hybridoma cell lines.

25 This invention further provides a polypeptide useful for generating the instant monoclonal antibody that comprises the amino acid sequence AAEGLDTQRFSG. In the preferred embodiment, the polypeptide is the polypeptide designated CD8-3 and having the amino acid sequence
30 AAEGLDTQRFSG. The instant polypeptide can optionally comprise one or more additional amino acid residues at the C-terminal or N-terminal end. In the preferred embodiment, the polypeptide has the sequence NKPKAAEGLDTQRFSGKRLG.

This invention further provides a population of CD8⁺ cells isolated by the instant method.

5 Finally, this invention provides a kit for use in isolating CD8⁺ cells which comprises, in separate compartments, (a) an antibody which specifically binds to the sequence AAEGLDTQRFSG, or portion thereof, on CD8 molecules present on the surface of CD8⁺ cells, but does
10 not activate the CD8⁺ cells once bound thereto; and (b) an agent which causes the dissociation of a CD8⁺ cell-antibody complex. In one embodiment, the agent which causes the dissociation of a CD8⁺ cell-antibody complex comprises the polypeptide having the sequence
15 AAEGLDTQRFSG. In the preferred embodiment, the agent is the polypeptide consisting of the sequence AAEGLDTQRFSG.

The instant kit can further comprise reagents useful for performing the binding and dissociation steps of the
20 instant method. The components of the instant kit can either be obtained commercially or made according to well known methods in the art. In addition, the components of the instant kit can be in solution or lyophilized as appropriate. In the preferred embodiment, the kit further
25 comprises instructions for use.

The following procedures relating to the instant invention are routine in the art: isolating peripheral mononuclear blood cells from which the CD8⁺ cells are in
30 turn isolated [6]; separating unbound antibodies and cells from a sample containing bound antibodies and/or cells via centrifugation or spinning membrane; and immobilizing antibodies via polystyrene flasks, columns or beads [4,7].

This invention will be better understood by reference to the Experimental Details which follow, but those skilled in the art will readily appreciate that the specific experiments detailed are only illustrative of the invention
5 as described more fully in the claims which follow thereafter.

Experimental Details

Rationale

5 Human CD8⁺ cells can be isolated from preparations of peripheral blood mononuclear cells (PBMC's) by either positive or negative selection. Positive selection results in a highly-purified population of CD8⁺ cells. Negative selection, while resulting in sufficient numbers
10 of CD8⁺ cells, has low levels of contaminating non-CD8 populations remaining after the selection procedure.

The idea was to generate an antibody which has high affinity for CD8⁺ cells, does not activate the cells
15 during the selection process, and is capable of being easily eluted from the cells. An anti-peptide antibody appeared to meet these criteria. However, it was known that anti-peptide antibodies might be of low affinity and may recognize the linear peptide sequence exclusively,
20 preventing reactivity with native antigen.

It was necessary that the anti-CD8 antibody not activate the cells during the selection process, as it would lessen their ability to effectively act as naïve
25 responder cells during in vitro stimulation protocols. The use of peptide release to selectively isolate a cell population has been shown by Tseng-Law, et al. [8] for CD34⁺ cells.

Methods

The CD8 alpha chain was examined for hydrophilic sequences and four peptides selected. All were coupled to keyhole limpet hemocyanin (KLH) as carrier and used to
5 immunize mice. A C-terminal amino acid was added to each of the peptides coupled to KLH to make the monoclonal antibodies. Antisera from the mice were evaluated for the ability to recognize both peptide and native CD8 on the surface of T cells. Only one of the four peptides was
10 capable of recognition of both antigenic forms of CD8. Monoclonal antibodies were generated to this peptide and the resulting antibody used to isolate CD8⁺ cells from a PBMC preparation. The antibody was successful in isolating a population of highly-purified CD8⁺ cells
15 (Table 1) which were not activated by the isolation procedure (Table 2).

Table 1

5 Purification of CD8⁺ Cells by
Positive Selection Analyzed by Flow Cytometry*

Cell Type	PEMO Purification (CD8 ⁺)	CD8 ⁺ Cells (%)
CD8 T cells	15 (7-24)	82 (56-95)
CD4 T cells	36 (14-52)	2 (0.1-10)
CD14 Monocytes	15 (7-26)	0.8 (0.2-2)
CD15 Neutrophils	12 (8-21)	0.6 (0.1-3)
CD19 B cells	2 (0.4-7)	3 (0.5-9)
CD56 NK cells	6 (2-17)	6 (0.1-20)

* Summary of 10 normal donors

10

Table 2

Activation of CD8⁺ Cells Isolated By Negative or
Positive Selection (Assessed by IFN γ Production)

Cells	Negative Selection (pg/ml)	Positive Selection (pg/ml)
un-stimulated	20	20
allo-stimulation	1440	3600

References

1. Nabholz M. and H.R. MacDonald (1983) Annual Review of Immunology 1:273-306.
- 5 2. Riddell S.R. and P.D. Greenberg (1994) Current Topics in Microbiology and Immunology 189:9-34.
3. Riddell S.R. and P.D. Greenberg (1995) Annual Review
10 of Immunology 13:545-586.
4. Horgan K and S. Shaw (1994) Current Protocols in Immunology 2:7.4.1.
- 15 5. Lea T, et al. (1988) Journal of Molecular Recognition 1(1):9-18.
6. Kanof, M.E., et al. (1994) Current Protocols in Immunology 2:7.1.1.
- 20 7. Kanof M.E. (1994) Current Protocols in Immunology 2:7:3:1.
8. PCT International Publication No. WO 95/34817.
- 25

What is claimed is:

1. A method of isolating CD8⁺ cells which comprises the steps of
 - 5 (a) contacting a sample of isolated peripheral mononuclear blood cells with a first antibody which specifically binds to the sequence AAEGLDTQRFSG, or portion thereof, on CD8 molecules present on the surface of CD8⁺ cells but does not activate the CD8⁺ cells once bound thereto, under conditions permitting the formation of a first complex between the CD8⁺ cell and first antibody;
 - 10 (b) separating from the sample any first antibody not present in the resulting first complex;
 - 15 (c) contacting the sample with a second, immobilized antibody which specifically binds to the first antibody in the first complex, under conditions permitting the formation of an immobilized, second complex between the first complex and the second antibody, thereby immobilizing the CD8⁺ cells present in the sample;
 - 20 (d) separating from the resulting immobilized second complex the cells present in the sample which were not immobilized in step (c);
 - 25 (e) contacting the immobilized second complex under suitable conditions with an agent which causes the dissociation of the second complex into CD8⁺ cells and an immobilized third complex between the first antibody and second antibody; and
 - 30 (f) separating the immobilized third complex from the CD8⁺ cells, thereby isolating the CD8⁺ cells.

2. The method of claim 1, wherein the CD8⁺ cells are human CD8⁺ cells.
3. The method of claim 1, wherein the first antibody is
5 a monoclonal antibody.
4. The method of claim 3, wherein the monoclonal antibody is produced by a hybridoma cell line selected from the group consisting of the cell line
10 designated 37B1 (ATCC Accession No. HB-12441) and the cell line designated 8G6 (ATCC Accession No. HB-12657).
5. The method of claim 1, wherein the immobilized second
15 antibody comprises an antibody operably affixed to a magnetic bead.
6. The method of claim 1, wherein the agent which causes the dissociation of immobilized third complex is the
20 polypeptide designated CD8-3 and having the amino acid sequence AAEGLDTQRFSG.
7. A hybridoma cell line which produces a monoclonal antibody which specifically binds to CD8 molecules
25 present on the surface of CD8⁺ cells but does not activate the CD8⁺ cells.
8. The hybridoma cell line of claim 7, wherein the hybridoma cell line is selected from the group
30 consisting of the cell line designated 37B1 (ATCC Accession No. HB-12441) and the cell line designated 8G6 (ATCC Accession No. HB-12657).

9. The monoclonal antibody produced by the hybridoma cell line of claim 7.
10. The monoclonal antibody produced by the hybridoma cell line of claim 8.
11. A polypeptide useful for generating the monoclonal antibody of claim 9 which comprises the amino acid sequence AAEGLDTQRFSG.
12. The polypeptide of claim 11, wherein the polypeptide is the polypeptide designated CD8-3 and having the amino acid sequence AAEGLDTQRFSG.
13. A population of CD8⁺ cells isolated by the method of claim 1.
14. A kit for use in isolating CD8⁺ cells which comprises, in separate compartments,
- (a) an antibody which specifically binds to the sequence AAEGLDTQRFSG, or portion thereof, on CD8 molecules present on the surface of CD8⁺ cells, but does not activate the CD8⁺ cells once bound thereto; and
- (b) an agent which causes the dissociation of a CD8⁺ cell-antibody complex.
15. The kit of claim 14, wherein the agent which causes the dissociation of a CD8⁺ cell-antibody complex is the polypeptide having the sequence AAEGLDTQRFSG.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/05898

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N5/06 C12N5/08 C12N5/20 C12P21/08 C07K16/28
C07K7/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 645 837 A (JAMESON ET AL) 8 July 1997 (1997-07-08) claims 1-18	11,12
A	EP 0 699 907 A (T CELL DIAGNOSTICS) 6 March 1996 (1996-03-06) claims 1-31	1-14
P,X	US 6 001 962 A (RAMER ET AL) 14 December 1999 (1999-12-14) column 25; claims 1-7	11,12
P,A	WO 99 54345 A (KORNGOLD R ET AL) 28 October 1999 (1999-10-28) claims 1-16	11,12

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

17 July 2000

Date of mailing of the international search report

08/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Le Flao, K

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. l. Application No

PCT/US 00/05898

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5645837	A	08-07-1997	WO 9622106 A	25-07-1996
EP 0699907	A	06-03-1996	US 5006459 A	09-04-1991
			AU 614928 B	19-09-1991
			AU 7126787 A	20-10-1987
			CA 1283045 A	16-04-1991
			EP 0261174 A	30-03-1988
			JP 1500367 T	09-02-1989
			WO 8705912 A	08-10-1987
			WO 9208981 A	29-05-1992
			WO 9208980 A	29-05-1992
			US 5292636 A	08-03-1994
			US 5426029 A	20-06-1995
US 6001962	A	14-12-1999	NONE	
WO 9954345	A	28-10-1999	NONE	